ERBB2 and breast carcinoma: The 2021 NCCN Breast Cancer Guidelines (6) state that adjuvant chemotherapy and targeted HER2 therapy are required for both categories of breast cancer after surgery, with the exception of HR-positive breast cancers, for which endocrine therapy is an additional option.